Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg Tablets – GLUMIGHT M2Tablets

Glumight M2 — Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg Tablets is a triple-combination medicine used for the management of type 2 diabetes mellitus. Glimepiride increases insulin release, metformin reduces glucose production and improves insulin sensitivity, while voglibose delays carbohydrate absorption after meals. Together, they help control post-meal sugar spikes, maintain stable blood glucose levels, and reduce the risk of diabetes-related complications when taken regularly with a proper diet and lifestyle.

Key Points of Glumight M2 Tablets — Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg Tablets: Triple Therapy for Comprehensive Type 2 Diabetes Management

Active Ingredients:

1. Glimepiride 2 mg — Sulfonylurea
2. Metformin 500 mg — Biguanide
3. Voglibose 0.2 mg — Alpha-glucosidase inhibitor

Therapeutic Benefits: Helps achieve effective control of type 2 diabetes mellitus by targeting multiple aspects of glucose regulation. Supports reduction of both fasting and post-meal blood sugar levels while improving overall glycaemic balance.
Better Tolerability: Well-balanced triple combination designed for enhanced glucose control with good tolerability when used under medical supervision.
Mode of Action: Glimepiride stimulates insulin secretion from pancreatic beta cells, Metformin reduces hepatic glucose production and improves insulin sensitivity, and Voglibose delays carbohydrate absorption from the intestine, together providing comprehensive and sustained blood glucose control.

Can be prescribed by:

• Diabetologists
• Endocrinologists
• General Physicians
• Healthcare practitioner

Disclaimer: To be used strictly under the guidance of a qualified healthcare professional. For prescription use only. Not intended for public marketing or promotion only.